Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C.
Romero-Gómez M, Gómez-González E, Madrazo A, Vera-Valencia M, Rodrigo L, Pérez-Alvarez R, Pérez-López R, Castellano-Megias VM, Nevado-Santos M, Alcón JC, Solá R, Pérez-Moreno JM, Navarro JM, Andrade RJ, Salmerón J, Fernández-López M, Aznar R, Diago M. Romero-Gómez M, et al. Among authors: diago m. Hepatology. 2008 Mar;47(3):810-6. doi: 10.1002/hep.22112. Hepatology. 2008. PMID: 18098299
Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP).
Carreño V, Marcellin P, Hadziyannis S, Salmerón J, Diago M, Kitis GE, Vafiadis I, Schalm SW, Zahm F, Manzarbeitia F, Jiménez FJ, Quiroga JA. Carreño V, et al. Among authors: diago m. Hepatology. 1999 Jul;30(1):277-82. doi: 10.1002/hep.510300117. Hepatology. 1999. PMID: 10385667 Clinical Trial.
Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virological response at week 4.
Sánchez-Tapias JM, Crespo J, Diago M, Pérez R, Romero-Gómez M, Muñoz-Sánchez M. Sánchez-Tapias JM, et al. Among authors: diago m. Methods Find Exp Clin Pharmacol. 2002 Nov;24(9):579-84. Methods Find Exp Clin Pharmacol. 2002. PMID: 12616704 Clinical Trial.
Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C.
Pérez R, Jiménez M, Crespo J, Diago M, Enríquez J, Vaquero P, Solá R, Olcoz JL, Romero M, Salmerón J, Blanco MI, Oña M, Melón S, Rodrigo L; Grupo Inter-Hospitalario Español. Pérez R, et al. Among authors: diago m. J Viral Hepat. 2003 Nov;10(6):437-45. doi: 10.1046/j.1365-2893.2003.00461.x. J Viral Hepat. 2003. PMID: 14633177 Clinical Trial.
Serum immunological profile in patients with chronic autoimmune cholestasis.
Romero-Gómez M, Wichmann I, Crespo J, Parés A, Rodrigo L, Alvarez A, Diago M, Pons-Romero F, Sanchez-Munoz D, Aguilar-Reina J, Andrade RJ, Salmeron J, Sánchez-Pobre P, Rebollo JM, Martin-Vivaldi R, Castellano-Megias V, Nuñez-Roldan A, Bruguera M; Spanish Group for the Study of Autoimmune Cholangitis. Romero-Gómez M, et al. Among authors: diago m. Am J Gastroenterol. 2004 Nov;99(11):2150-7. doi: 10.1111/j.1572-0241.2004.40416.x. Am J Gastroenterol. 2004. PMID: 15554996
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J. Romero-Gómez M, et al. Among authors: diago m. Gastroenterology. 2005 Mar;128(3):636-41. doi: 10.1053/j.gastro.2004.12.049. Gastroenterology. 2005. PMID: 15765399
HLA-C and KIR genes in hepatitis C virus infection.
Montes-Cano MA, Caro-Oleas JL, Romero-Gómez M, Diago M, Andrade R, Carmona I, Aguilar Reina J, Núñez-Roldán A, González-Escribano MF. Montes-Cano MA, et al. Among authors: diago m. Hum Immunol. 2005 Nov;66(11):1106-9. doi: 10.1016/j.humimm.2006.02.001. Epub 2006 Mar 9. Hum Immunol. 2005. PMID: 16571411
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.
Sánchez-Tapias JM, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R, Crespo J, Andrade R, Martínez-Bauer E, Pérez R, Testillano M, Planas R, Solá R, García-Bengoechea M, Garcia-Samaniego J, Muñoz-Sánchez M, Moreno-Otero R; TeraViC-4 Study Group. Sánchez-Tapias JM, et al. Among authors: diago m. Gastroenterology. 2006 Aug;131(2):451-60. doi: 10.1053/j.gastro.2006.05.016. Gastroenterology. 2006. PMID: 16890599 Clinical Trial.
Induction doses of interferon-alpha-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial.
Salmerón J, Diago M, Andrade R, Pérez R, Solá R, Romero M, de la Mata M, Granados R, Ruiz-Extremera A, Muñoz de Rueda P. Salmerón J, et al. Among authors: diago m. J Viral Hepat. 2007 Feb;14(2):89-95. doi: 10.1111/j.1365-2893.2006.00771.x. J Viral Hepat. 2007. PMID: 17244248 Clinical Trial.
Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate.
Diago M, Olveira A, Solá R, Romero-Gómez M, Moreno-Otero R, Pérez R, Salmerón J, Enríquez J, Planas R, Gavilán JC, Del Olmo J, Uribarrena R, Sillero C, Benítez A, Sánchez-Galdón S, Dalmau B, Eraña L, Montoro M, Portu J, Garijo JM, Barniol R, Domínguez A, Rota R, Olcoz JL, Antón M, Pamplona X, Casanovas T, Jiménez E, Huarte M, Díaz F, Sánchez-Ruano J, Orive M, Muñoz-Sánchez M, Roset M. Diago M, et al. Aliment Pharmacol Ther. 2007 Apr 15;25(8):899-906. doi: 10.1111/j.1365-2036.2007.03270.x. Aliment Pharmacol Ther. 2007. PMID: 17402993 Free article. Clinical Trial.
225 results